A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT

Bone Marrow Transplantation

Volumn 46, Issue 2, 2011, Pages 294-299

  Klein, A ^a   Miller, K B ^a   Sprague, K ^a   Desjardin, J A ^a   Snydman, D R ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

SCT; valacyclovir prophylaxis; VZV

Indexed keywords

ACICLOVIR; FAMCICLOVIR; MYCOPHENOLIC ACID; PLACEBO; PREDNISONE; VALACICLOVIR;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTHRALGIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; INFECTION PREVENTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; THROMBOCYTOPENIA; TREATMENT DURATION; VARICELLA ZOSTER VIRUS; VIRUS INHIBITION; VIRUS REACTIVATION;

EID: 85027928908     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.99     Document Type: Article

References (34)

1. Arvin AM. Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2000; 6: 219-230.
2. Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. Ann Intern Med 1999; 130: 922-932. (Pubitemid 29239587)
3. Ku CC, Besser J, Abendroth A, Grose C, Arvin AM. Varicella-zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol 2005; 79: 2651-2658. (Pubitemid 40270543)
4. Levin MJ, Hayward AR. The varicella vaccine. Prevention of herpes zoster. Infect Dis Clin North Am 1996; 10: 657-675. (Pubitemid 26285293)
5. Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation-a randomized double-blind placebo-controlled study. Blood 2006; 107: 1800-1805. (Pubitemid 43289356)
6. Erard V, Guthrie KA, Varley C, Heugel J, Wald A, Flowers ME et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007; 110: 3071-3077. (Pubitemid 350006963)
7. Kanda Y, Mineishi S, Saito T, Saito A, Yamada S, Ohnishi M et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 689-692. (Pubitemid 33014603)
8. Kim DH, Messner H, Minden M, Gupta V, Kuruvilla J, Wright J et al. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis 2008; 10: 90-98. (Pubitemid 351393079)
9. Ljungman P, Wilczek H, Gahrton G, Gustavsson A, Lundgren G, Lonnqvist B et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant 1986; 1: 185-192. (Pubitemid 18048960)
10. Perren TJ, Powles RL, Easton D, Stolle K, Selby PJ. Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Am J Med 1988; 85: 99-101.
11. Sempere A, Sanz GF, Senent L, de la RJ, Jarque I, Lopez F et al. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia. Bone Marrow Transplant 1992; 10: 495-498. (Pubitemid 23024732)
12. Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 2000; 25: 657-664. (Pubitemid 30156592)
13. Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005; 35: 1065-1069. (Pubitemid 40767194)
14. Brigden D, Fiddian P, Rosling AE, Ravenscroft T. Acyclovir - a review of the preclinical and early clinical data of a new antiherpes drug. Antiviral Res 1981; 1: 203-212. (Pubitemid 12202594)
15. Balfour Jr HH, McMonigal KA, Bean B. Acyclovir therapy of varicella-zoster virus infections in immunocompromised patients. J Antimicrob Chemother 1983; 12 (Suppl B): 169-179. (Pubitemid 14228012)
16. Serota FT, Starr SE, Bryan CK, Koch PA, Plotkin SA, August CS. Acyclovir treatment of herpes zoster infections. Use in children undergoing bone marrow transplantation. JAMA 1982; 247: 2132-2135. (Pubitemid 12139594)
17. Wade JC, Newton B, McLaren C, Flournoy N, Keeney RE, Meyers JD. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med 1982; 96: 265-269. (Pubitemid 12187499)
18. Balfour Jr HH, Bean B, Laskin OL, Ambinder RF, Meyers JD, Wade JC et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983; 308: 1448-1453. (Pubitemid 13103445)
19. Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995; 28: 281-290.
20. Jacobson MA. Valaciclovir (BW256U87): the L-valyl ester of acyclovir. J Med Virol 1993: (Suppl 1): 150-153. (Pubitemid 23290502)
21. Koc Y, Miller KB, Schenkein DP, Griffith J, Akhtar M, DesJardin J et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000; 6: 44-49.
22. Christiansen NP, Haake RJ, Hurd DD. Early herpes zoster infection in adult patients with Hodgkin's disease undergoing autologous bone marrow transplant. Bone Marrow Transplant 1991; 7: 435-437.
23. Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994; 13: 277-283. (Pubitemid 24065953)
24. Ljungman P, Lonnqvist B, Gahrton G, Ringden O, Sundqvist VA, Wahren B. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J Infect Dis 1986; 153: 840-847. (Pubitemid 16114859)
25. Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985; 152: 1172-1181. (Pubitemid 16215593)
26. Schuchter LM, Wingard JR, Piantadosi S, Burns WH, Santos GW, Saral R. Herpes zoster infection after autologous bone marrow transplantation. Blood 1989; 74: 1424-1427. (Pubitemid 19227457)
27. Arora A, Mendoza N, Brantley J, Yates B, Dix L, Tyring S. Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older. J Infect Dis 2008; 197: 1289-1295. (Pubitemid 351632760)
28. Jacobson MA, Gallant J, Wang LH, Coakley D, Weller S, Gary D et al. Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 1994; 38: 1534-1540. (Pubitemid 24203565)
29. Madkan VK, Arora A, Babb-Tarbox M, Aboutlabeti S, Tyring S. Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older. J Cutan Med Surg 2007; 11: 89-98.
30. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000; 9: 863-869.
31. Ljungman P, de la CR, Milpied N, Volin L, Russell CA, Crisp A et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002; 99: 3050-3056. (Pubitemid 34525398)
32. Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied N, Fernandez Ranada JM et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343: 749-753. (Pubitemid 24098690)
33. Sano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008; 83: 472-476. (Pubitemid 351742795)
34. Dykewicz CA, Kaplan JE, Jaffe HW, for the Centres for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49 (RR-10): 1-7.